Scotiabank Begins Coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY)
Scotiabank started coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research note issued to ...
Prothena: Delays And Data Uncertainty Undermine Case For Investing (Downgrade)
Prothena Corporation plc's stock has dropped 67% since my last “Buy” rating, primarily due to delays and a lack of meaningful ...
Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU
ALNY stock gains after submitting a regulatory application in the EU, seeking the approval of vutrisiran to treat ATTR ...
Managed Healthcare Executive5d
With New Drugs in the Offing, Treatment Cost of ATTR-CM Is Projected to Climb | AMCP Nexus 2024
Several companies are developing new drugs treat transthyretin amyloidosis cardiomyopathy (ATTR-CM), an formerly obscure ...
Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced the submission of a Type II Variation to the European Medicines Agency (EMA) for ...
Alnylam Pharma Submits Type II Variation To European Medicines Agency For Vutrisiran
Alnylam Pharmaceuticals (ALNY) announced the submission of a Type II Variation to the European Medicines Agency for vutrisiran, an ...
Alnylam Pharmaceuticals (NASDAQ:ALNY) Sets New 12-Month High After Analyst Upgrade
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report)’s stock price reached a new 52-week high on Tuesday after Bank of America raised their price target on the stock from $307.00 to $314.00.